What is it?
What pregnenolone is
1Pregnenolone is an endogenous steroid hormone precursor and neurosteroid. The retained human evidence is mostly clinical and psychiatric rather than healthy-user nootropic evidence.
Names and identity
1Pregnenolone is also listed as 3beta-hydroxypregn-5-en-20-one. Its public identity fields refer to pregnenolone itself, not the distinct sulfated derivative pregnenolone sulfate.
Names, aliases and forms
Mechanisms of action
Steroid-hormone precursor
1Pregnenolone can feed downstream neurosteroid and steroid-hormone pathways. That biology is relevant to safety and variability, but it should not be used as stand-alone evidence for memory, mood or anti-aging claims.
GABA and glutamate mechanisms are indirect
2Clinical papers discuss pregnenolone sulfate, allopregnanolone, GABA and NMDA/glutamate mechanisms. These are plausible explanations for research signals, not proof of predictable nootropic effects in healthy buyers.
Potential effects and evidence map
Pregnenolone has randomized human studies, but they are mostly adjunctive psychiatric trials. Schizophrenia studies show mixed cognitive findings: one larger 8-week trial did not improve cognitive symptoms, while a recent-onset schizophrenia trial reported visual-attention and executive-function signals. Bipolar depression and dual-diagnosis studies suggest mood-related signals in selected populations. These short, population-specific trials do not establish broad healthy-user nootropic benefits or long-term self-directed use.
Selected psychiatric trials suggest mood-related signals, especially in bipolar depression, but this does not establish general mood enhancement for healthy users.
Cognitive findings are mixed in schizophrenia trials and do not support broad memory claims.
Anxiety or stress-related interpretations remain indirect and population-specific.
Typical dosages and timing
Published trials used doses such as 50 mg/day or titration up to 500 mg/day. These are clinical-study contexts, not consumer targets.
Timing & effect horizon
Most cited human studies measured outcomes over weeks. This should not be read as onset, cycle length or duration of effect for healthy users.
Safety, side effects and risk profile
Pregnenolone is a hormone precursor, but the retained short trials do not establish routine safety for hormone-sensitive conditions or endocrine-active regimens.
The retained clinical evidence does not establish safety during pregnancy or lactation; this profile does not provide a dose or use recommendation for either context.
The retained studies do not establish routine combination safety with medicines, hormone-active treatments or supplement stacks. FDA advises discussing dietary supplements with a clinician or pharmacist because supplements can interact with medicines or other supplements.
In one 4-week active-treatment trial up to 500 mg/day, insomnia occurred in 1 of 45 participants and in none of 49 placebo participants; the selected short trial cannot estimate routine consumer risk.
In the same 4-week active-treatment trial, diarrhea occurred in 1 of 45 participants and in none of 49 placebo participants; the selected short trial cannot estimate routine consumer risk.
United States supplement regulation and athlete eligibility are jurisdiction- and organization-specific checks, not a general safety rating. Athletes should verify current status with the relevant anti-doping organization.
The retained studies are short and in selected clinical populations, so they do not establish a healthy-adult base risk or long-term self-directed safety.
In a registry-reported chronic-pain trial with 4 weeks of active, escalating oral treatment up to 500 mg/day, 0 of 45 pregnenolone participants had a serious adverse event. Insomnia and diarrhea each occurred in 1 of 45 pregnenolone participants, versus 0 of 49 placebo participants. This selected short trial does not quantify long-term or healthy-user safety.
Interactions and cautions
The cited studies are not interaction studies and do not establish routine combination safety with prescription medicines, hormone-active treatments or supplement stacks. FDA advises consumers to discuss dietary supplements with a doctor, pharmacist or other health professional because supplements can interact with medicines or other supplements.
Legal and regulatory status
United States context (as of 2026): FDA does not approve dietary supplements or their labeling before marketing, although manufacturers remain responsible for complying with applicable safety and labeling rules. This general framework does not determine the legal status of a specific pregnenolone product or make disease, hormone, fertility, mood or cognition claims appropriate.
United States athlete context (as of 2026): USADA says pregnenolone is not currently on the WADA Prohibited List, while directing athletes to re-check its status through Global DRO. WADA updates its List annually, and the relevant sport or national rules control eligibility; this profile cannot determine a product or batch status.
Practical buying and quality notes
- Before comparing offers, check whether the seller identifies the ingredient and states the amount per serving. In the United States, supplement labels must identify dietary ingredients and generally state the amount per serving.7
- Compare the stated pregnenolone amount per serving, capsules per bottle, serving flexibility, and whether a listing is a single ingredient or a blend. Do not compare prices before confirming the labeled amount.7
- Prefer listings that clearly identify every ingredient and amount. A product advertised as pregnenolone may be a blend, so compare the listed formula before comparing price.7
FAQ
Is pregnenolone a proven nootropic?
3No. It has clinical neuropsychiatric research, but that does not establish reliable healthy-adult memory, focus or productivity benefits.
What dose has been studied?
5The cited psychiatric studies used trial-specific regimens. They are clinical-study context, not a recommendation for personal dosing.
Who should be most cautious?
7FDA advises people considering a dietary supplement to discuss it with a doctor, pharmacist or other health professional, including because supplements may interact with medicines or other supplements. The retained studies do not establish routine use in pregnancy, lactation, hormone-sensitive or hormone-treatment contexts.
References
- PubChem. Pregnenolone. Compound CID 8955.
- Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology. 2009;34(8):1885-1903.
- Marx CE, Lee J, Subramaniam M, Rapisarda A, Bautista DC, et al. Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology (Berl). 2014;231(17):3647-3662.
- Kreinin A, Bawakny N, Ritsner MS. Adjunctive Pregnenolone Ameliorates the Cognitive Deficits in Recent-Onset Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Clin Schizophr Relat Psychoses. 2017;10(4):201-209.
- Brown ES, Park J, Marx CE, Hynan LS, Gardner C, et al. A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression. Neuropsychopharmacology. 2014;39(12):2867-2873.
- Osuji IJ, Vera-Bolanos E, Carmody TJ, Brown ES. Pregnenolone for cognition and mood in dual diagnosis patients. Psychiatry Res. 2010;178(2):309-312.
- US Food and Drug Administration. Questions and Answers on Dietary Supplements.
- US Food and Drug Administration. Dietary Supplements.
- World Anti-Doping Agency. 2026 Prohibited List, effective 1 January 2026.
- ClinicalTrials.gov. NCT01898013: Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans. Results posted.
- U.S. Anti-Doping Agency. Pregnenolone: What You Need to Know.